Show simple item record

dc.contributor.authorBasturk, Taner
dc.contributor.authorSever, Mehmet Sukru
dc.contributor.authorSeyahi, Nurhan
dc.contributor.authorYILDIZ, ABDULMECİT
dc.contributor.authorKilicaslan, Isin
dc.contributor.authorSarihan, Irem
dc.contributor.authorCaliskan, Yasar
dc.contributor.authorMİRİOĞLU, ŞAFAK
dc.contributor.authorOzluk, Yasemin
dc.contributor.authorSenates, Banu
dc.date.accessioned2021-03-02T17:32:00Z
dc.date.available2021-03-02T17:32:00Z
dc.date.issued2020
dc.identifier.citationSarihan I., Caliskan Y., MİRİOĞLU Ş., Ozluk Y., Senates B., Seyahi N., Basturk T., YILDIZ A., Kilicaslan I., Sever M. S. , "Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality", TRANSPLANTATION, cilt.104, ss.1703-1711, 2020
dc.identifier.issn0041-1337
dc.identifier.othervv_1032021
dc.identifier.otherav_92e1afe3-5d99-41cd-90f7-9c2f9ba26d9f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3946
dc.identifier.urihttps://doi.org/10.1097/tp.0000000000003043
dc.description.abstractBackground. There are limited data on the outcome of transplant recipients with familial Mediterranean fever (FMF)-associated AA amyloidosis. The aim of the present study is to evaluate demographic, clinical, laboratory, and prognostic characteristics and outcome measures of these patients. Methods. Eighty-one renal transplant recipients with FMF-associated AA amyloidosis (group 1) and propensity score-matched transplant recipients (group 2, n = 81) with nonamyloidosis etiologies were evaluated in this retrospective, multicenter study. Recurrence of AA amyloidosis was diagnosed in 21 patients (group 1a), and their features were compared with 21 propensity score-matched recipients with FMF amyloidosis with no laboratory signs of recurrence (group 1b). Results. The risk of overall allograft loss was higher in group 1 compared with group 2 (25 [30.9%] versus 12 [14.8%];P= 0.015 [hazard ratio, 2.083; 95% confidence interval, 1.126-3.856]). Patients in group 1 were characterized by an increased risk of mortality compared with group 2 (11 [13.6%] versus 0%;P= 0.001 [hazard ratio, 1.136; 95% confidence interval, 1.058-1.207]). Kaplan-Meier analysis revealed that 5- and 10-year patient survival rates in group 1 (92.5% and 70.4%) were significantly lower than in group 2 (100% and 100%;P= 0.026 andP= 0.023, respectively). Although not reaching significance, overall, 5- and 10-year graft survival rates (57.1%, 94.7%, and 53.8%, respectively) in group 1a were worse than in group 1b (76.2%, 95%, and 77.8%, respectively;P= 0.19,P= 0.95, andP= 0.27, respectively). Conclusions. AA amyloidosis is associated with higher risk of mortality after kidney transplantation. Inflammatory indicators should be monitored closely, and persistent high levels of acute-phase reactants should raise concerns about amyloid recurrence in allograft.
dc.language.isoeng
dc.subjectCerrahi Tıp Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectKlinik Tıp (MED)
dc.subjectTRANSPLANTASYON
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectCERRAHİ
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.titleAmyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality
dc.typeMakale
dc.relation.journalTRANSPLANTATION
dc.contributor.departmentİstanbul Teknik Üniversitesi , ,
dc.identifier.volume104
dc.identifier.issue8
dc.identifier.startpage1703
dc.identifier.endpage1711
dc.contributor.firstauthorID2285248


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record